How can get structured therapies in metastatic cancer a source for detecting tumor-associated systems-biological processes as adjustable sizes available for biomodulatory therapies?
A therapy-derived methodological approach to explore tumor-associated systems biology should be explicated and developed by means of analyses of recently published biomodulatory therapy approaches introducing combined anti-inflammatory; angiostatic; and immunomodulatory therapy in the treatment for advanced chemorefractory tumors of quite different origin. Biomodulatory therapy approaches in tumors intend to develop systems-terms that provide a basis for broadening therapy-relevant capacities by regulating biological systems processes for tumor control. Combined targeted therapies of tumor-associated wound healing mechanisms, namely inflammation and neoangiogenesis, have shown that – using an approach for understanding systems biology as adjustable size – we may break through the barrier of complexity of tumor-stroma-interactions in a therapeutically relevant way. Targeting the tumor systems’ topology of aggregated action effects (inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects) may open up the perspective of individualized tumor therapy.